Engineering Immune Response Small Molecule 
Broad Institute
OCTOBER 4, 2023
By Allessandra DiCorato October 4, 2023 Credit: AbbVie The new small molecule inhibitor (green) sits inside the PTPN2 protein, where acidic sites are marked in red and basic sites are marked in blue. A new small-molecule drug candidate being tested in an early-stage clinical trial aims to improve patient responses to immunotherapy.
Drug Target Review
DECEMBER 4, 2024
The MC4R-based ConfoGen was used to immunize llamas, resulting in an immune response that generated a highly diverse panel of MC4R-specific agonists. In addition to generating agonistic antibodies, Confo is also successfully applying the ConfoBody/ConfoChimer technology to drugging GPCR with small molecules.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Target Review
NOVEMBER 7, 2024
Agonist antibodies of immune checkpoint regulators These represent a groundbreaking class of immunotherapeutic agents that mimic the natural function of endogenous ligands by binding to specific cell-surface receptors. In these conditions, the goal of therapy is typically to suppress or mitigate immune activity.
The Pharma Data
JANUARY 17, 2021
Johnson & Johnson published interim Phase I/IIa data in the New England Journal of Medicine showing its single-dose COVID-19 vaccine candidate created an immune response that lasted at least 71 days. The data showed that the vaccine induced an immune response and was generally well-tolerated. Most Read Today.
Advarra
JANUARY 11, 2024
After injection of such a vaccine, the mRNA instructs cells to produce proteins designed to stimulate an immune response against these same protein targets when they show up in viruses or in tumor cells. Adoptive T Cell Therapies Adoptive T cell therapy is another form of cancer treatment leveraging the patient’s immune system.
The Pharma Data
APRIL 22, 2023
These “acute inflammatory lesions” then attract other myeloid cells, as well as self-reactive T and B cells that belong to the immune system’s second arm, known as the “adaptive immune system” and directly attack the myelin covering. “Current MS therapies do not specifically target myeloid cells. .
The Pharma Data
OCTOBER 27, 2020
Be Bio plans to use their $52 million Series A to precisely engineer B cells to treat a range of diseases. Primmune aims to advance the development of their novel orally-administered, small molecule toll-like receptor 7 agonists as therapeutic-adjuvants for acute viral diseases and cancer. said of B cells’ potential.
Expert insights. Personalized for you.
128 
Let's personalize your content